Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pietro Castellan, Roberto Castellucci, Michele Marchioni, Cosimo De Nunzio, Giorgia Tema, Giulia Primiceri, Luigi Schips & Luca Cindolo. (2019) A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. Expert Opinion on Drug Safety 18:9, pages 759-767.
Read now
Read now
Subo Qian, Jia Xia, Hailong Liu, Yu Zhang, Lin Zhang & Yongjiang Yu. (2018) Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. The Aging Male 21:4, pages 231-237.
Read now
Read now
Jianhong Zhu, Rifang Liao, Chen Su, Dan Liang, Junyan Wu, Kaifeng Qiu & Jianfang Li. (2018) Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert Review of Anticancer Therapy 18:2, pages 193-198.
Read now
Read now
Axel S Merseburger, Antonio Alcaraz & Christoph A von Klot. (2016) Androgen deprivation therapy as backbone therapy in the management of prostate cancer. OncoTargets and Therapy 9, pages 7263-7274.
Read now
Read now
Chiara Ciccarese, Elisabetta Nobili, Donatella Grilli, Laura Casolari, Karim Rihawi, Francesco Gelsomino, Giampaolo Tortora & Francesco Massari. (2016) The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Review of Anticancer Therapy 16:7, pages 681-696.
Read now
Read now
Mutahir Tunio, Mushabbab Al Asiri, Abdulrehman Al Hadab & Yasser Bayoumi. (2015) Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy 9, pages 5291-5299.
Read now
Read now
Articles from other publishers (30)
Lucas Germain, Camille Lafront, Virginie Paquette, Bertrand Neveu, Jean-Sébastien Paquette, Frédéric Pouliot & Étienne Audet-Walsh. (2023) Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. Nature Reviews Urology 20:8, pages 480-493.
Crossref
Crossref
Xiangguo Meng, Siju Bi, Shixin Jin, Kai Wu, Shanchao Wu, Lei Shao, Pierre-Antoine Bonnet & Chunquan Sheng. (2023) A novel route for the synthesis of androgen receptor antagonist enzalutamide. Chinese Chemical Letters 34:6, pages 108096.
Crossref
Crossref
Liliana Burlibasa, Alina-Teodora Nicu, Mariana Carmen Chifiriuc, Cosmin Medar, Amelia Petrescu, Viorel Jinga & Ileana Stoica. (2023) H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Julia Kallenbach, Golnaz Atri Roozbahani, Mehdi Heidari Horestani & Aria Baniahmad. (2022) Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. Cell & Bioscience 12:1.
Crossref
Crossref
Wu Du. (2022) Advances in AR-targeting chimeras: a case study of proteolysis-targeting chimeras from bench to bedside. Future Medicinal Chemistry 14:20, pages 1471-1489.
Crossref
Crossref
Xin Han & Yi Sun. (2022) Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. Cell Reports Physical Science 3:10, pages 101062.
Crossref
Crossref
Daiki Yamamoto, Katsumasa Sasaki, Takeo Kosaka, Mototsugu Oya & Toshinori Sato. (2022)
Functional analysis of
GCNT3
for cell migration and EMT of castration-resistant prostate cancer cells
. Glycobiology.
Crossref
Crossref
Andrea Leith, Jeri Kim, Amanda Ribbands, Emily Clayton, Lingfeng Yang & Sameer R. Ghate. (2022) Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan. Advances in Therapy 39:5, pages 2236-2255.
Crossref
Crossref
Jae Duck Choi, Tae Jin Kim, Byong Chang Jeong, Hwang Gyun Jeon, Seong Soo Jeon, Min Yong Kang, Seon Yong Yeom & Seong Il Seo. (2021) ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). Scientific Reports 11:1.
Crossref
Crossref
Shunsuke Tsuzuki, Shotaro Nakanishi, Mitsuyoshi Tamaki, Takuma Oshiro, Jun Miki, Hiroki Yamada, Tatsuya Shimomura, Takahiro Kimura, Nozomu Furuta, Seiichi Saito & Shin Egawa. (2021) Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. PLOS ONE 16:10, pages e0258160.
Crossref
Crossref
Xin Han, Lijie Zhao, Weiguo Xiang, Chong Qin, Bukeyan Miao, Donna McEachern, Yu Wang, Hoda Metwally, Lu Wang, Aleksas Matvekas, Bo Wen, Duxin Sun & Shaomeng Wang. (2021) Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry 64:17, pages 12831-12854.
Crossref
Crossref
Ruixin Wang & Xiaoqi Liu. (2020) Epigenetic regulation of prostate cancer. Genes & Diseases 7:4, pages 606-613.
Crossref
Crossref
Holger H. H. Erb, Julia Bodenbender, Florian Handle, Tamara Diehl, Lukas Donix, Igor Tsaur, Martin Gleave, Axel Haferkamp, Johannes Huber, Susanne Fuessel, Eva Juengel, Zoran Culig & Christian Thomas. (2020) Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLOS ONE 15:8, pages e0237248.
Crossref
Crossref
Miriam Kokal, Kimia Mirzakhani, Thanakorn Pungsrinont & Aria Baniahmad. (2020) Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer. Cancers 12:7, pages 1833.
Crossref
Crossref
Cheng Hu, Hongyan Xia, Shanshan Bai, Jianlei Zhao, Holly Edwards, Xinyu Li, Yanrong Yang, Jing Lyu, Guan Wang, Yang Zhan, Yan Dong & Yubin Ge. (2020) CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. Journal of Cellular and Molecular Medicine 24:13, pages 7239-7253.
Crossref
Crossref
Xianling Yuan, Jiayan Shen, Xinyue Zhang, Wenqing Tu, Zhengwei Fu & Yuanxiang Jin. (2020) Imidacloprid disrupts the endocrine system by interacting with androgen receptor in male mice. Science of The Total Environment 708, pages 135163.
Crossref
Crossref
Andrea Eigentler, Piotr Tymoszuk, Johanna Zwick, Arndt A. Schmitz, Andreas Pircher, Florian Kocher, Andreas Schlicker, Ralf Lesche, Georg Schäfer, Igor Theurl, Helmut Klocker & Isabel Heidegger. (2020) The Impact of Cand1 in Prostate Cancer. Cancers 12:2, pages 428.
Crossref
Crossref
Romina Armando, Diego Mengual G�mez & Daniel Gomez. (2020) New drugs are not enough‑drug repositioning in oncology: An update. International Journal of Oncology.
Crossref
Crossref
Yunfeng Bai, Zhuangzhuang Zhang, Lijun Cheng, Ruixin Wang, Xiaoliang Chen, Yifan Kong, Feng Feng, Nihal Ahmad, Lang Li & Xiaoqi Liu. (2019) Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. Journal of Biological Chemistry 294:25, pages 9911-9923.
Crossref
Crossref
Pedro C. Barata & A. Oliver Sartor. (2019) Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…. Cancer 125:11, pages 1777-1788.
Crossref
Crossref
Cora N Sternberg. (2019) Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncology 15:13, pages 1437-1457.
Crossref
Crossref
Yifan Kong, Lijun Cheng, Fengyi Mao, Zhuangzhuang Zhang, Yanquan Zhang, Elia Farah, Jacob Bosler, Yunfeng Bai, Nihal Ahmad, Shihuan Kuang, Lang Li & Xiaoqi Liu. (2018) Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). Journal of Biological Chemistry 293:37, pages 14328-14341.
Crossref
Crossref
Neal D. Shore, Teuvo L. Tammela, Christophe Massard, Petri Bono, John Aspegren, Mika Mustonen & Karim Fizazi. (2018) Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. European Urology Focus 4:4, pages 547-553.
Crossref
Crossref
Kelly Stratton & Michael Cookson. (2017) Castration-Resistant Prostate Cancer. Urologic Clinics of North America 44:4, pages 647-655.
Crossref
Crossref
Junlong Wu, Guowen Lin, Yao Zhu, Hailiang Zhang, Guohai Shi, Yijun Shen, Yiping Zhu, Bo Dai & Dingwei Ye. (2017) Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. Scientific Reports 7:1.
Crossref
Crossref
Giuseppe Galletti, Benjamin I. Leach, Linda Lam & Scott T. Tagawa. (2017) Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treatment Reviews 57, pages 16-27.
Crossref
Crossref
Jie Li, Ruixin Wang, Yifan Kong, Meaghan M. Broman, Colin Carlock, Long Chen, Zhiguo Li, Elia Farah, Timothy L. Ratliff & Xiaoqi Liu. (2017) Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics 16:3, pages 469-479.
Crossref
Crossref
Long Chen, Jie Li, Elia Farah, Sukumar Sarkar, Nihal Ahmad, Sanjay Gupta, James Larner & Xiaoqi Liu. (2016) Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. Molecular Cancer Therapeutics 15:9, pages 2107-2118.
Crossref
Crossref
F. Labrize, L. Cany, C. Massard, Y. Loriot, P. Sargos, M. Gross-Goupil & G. Roubaud. (2016) Enzalutamide and sleep apnea: an emerging central nervous system side-effect?. Annals of Oncology 27:1, pages 206.
Crossref
Crossref
Juan Fernando Uribe Arcila. (2016) Vía trasera de la síntesis de testosterona (backdoor pathway). Urología Colombiana 25:1, pages 25-30.
Crossref
Crossref